ORAMED PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
ORMP$4.00+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $9,055 | $40,464 |
| Short-term deposits (note 2) | 95,279 | 111,513 |
| Marketable securities (note 3) | - | 3,743 |
| Investments at fair value (note 4) | 57,713 | - |
| Prepaid expenses and other current assets | 537 | 1,389 |
| Total current assets | 162,584 | 157,109 |
| LONG-TERM ASSETS: | ||
| Long-term deposits | 7 | 7 |
| Investments at fair value (note 4) | 51,035 | - |
| Marketable securities (note 3) | 1,807 | - |
| Other non-marketable equity securities (note 5) | 3,524 | 2,700 |
| Amounts funded in respect of employee rights upon retirement | 27 | 24 |
| Property and equipment, net | 873 | 815 |
| Operating lease right of use assets | 694 | 987 |
| Total long-term assets | 57,967 | 4,533 |
| Total assets | $220,551 | $161,642 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses (note 6) | $1,609 | $4,158 |
| Short-term borrowings (note 7) | 51,013 | - |
| Deferred revenues | - | 1,340 |
| Payable to related parties (note 13b) | 325 | 1 |
| Operating lease liabilities | 267 | 247 |
| Total current liabilities | 53,214 | 5,746 |
| LONG-TERM LIABILITIES: | ||
| Long-term deferred revenues | 4,000 | 4,000 |
| Employee rights upon retirement | 28 | 21 |
| Provision for uncertain tax position (note 12f) | 11 | 11 |
| Operating lease liabilities | 342 | 647 |
| Other liabilities | 63 | 61 |
| Total long-term liabilities | 4,444 | 4,740 |
| COMMITMENTS (note 8) | ||
| EQUITY | ||
| EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS’: | ||
| Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2023 and December 31, 2022; 40,338,979 and 39,563,888 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively) | 485 | 476 |
| Additional paid-in capital | 320,892 | 314,417 |
| Accumulated deficit | (157,556) | (163,081) |
| Total stockholders’ equity | 163,821 | 151,812 |
| Non-controlling interests | (928) | (656) |
| Total equity | 162,893 | 151,156 |
| Total liabilities and equity | $220,551 | $161,642 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.